Screener
CG Oncology CGON Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Withholding taxes paid on net exercise of stock options | (194) | — |
| Stock issuance costs | (186) | (547) |
| Net cash provided by financing activities | 394,920 | 154 |
| Net decrease in cash and cash equivalents | (12,854) | (242,444) |
| Cash and cash equivalents at beginning of period | 32,490 | 257,068 |
| Cash and cash equivalents at end of period | $19,636 | $14,624 |
| Supplemental Disclosure of Cash Flow Information | ||
| Cash paid for interest | $94 | — |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's net change in cash?
- CG Oncology (CGON) reported net change in cash of -$14.06M in Q2 2026.
- How has CG Oncology's net change in cash changed year-over-year?
- CG Oncology's net change in cash increased by 47.6% year-over-year, from -$26.85M to -$14.06M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about CG Oncology's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude